Announcements Trials
Browse Landscape

Phase

Phase 2 132Phase 1 19Phase 3 16Phase 1/2 11Phase NA 3Phase 4 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

The Neoadjuvant Therapy 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Fulvestrant × Clear all
NCT02692755 2021-09-28

PALINA

Georgetown University

Phase 2/3 Completed
35 enrolled 12 charts
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Phase 2/3 Unknown
120 enrolled

The Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡